重新审视射血分数保留的心力衰竭中的β受体阻滞剂治疗
Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction.
作者信息
Kaddoura Rasha, Patel Ashfaq
机构信息
Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
出版信息
Curr Probl Cardiol. 2023 Dec;48(12):102015. doi: 10.1016/j.cpcardiol.2023.102015. Epub 2023 Aug 6.
Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a current cut-off of ≥50%. The evidence of beta-blocker therapy in HFpEF patients showed conflicting findings with variably reported efficacy. This review aims to examine the published studies on the use of beta blockers for the treatment of patients with HFpEF.
射血分数保留的心力衰竭（HFpEF）是一种异质性疾病，在老年、女性和肥胖患者中更为常见。在已发表的研究中，HFpEF根据左心室射血分数的不同临界值进行分类，目前的临界值为≥50%。关于β受体阻滞剂治疗HFpEF患者的证据显示结果相互矛盾，疗效报道不一。本综述旨在研究已发表的关于使用β受体阻滞剂治疗HFpEF患者的研究。
Zotero 插件